Table 1.

Anti-HIV and HCV mAbs in clinical development.

Compound	Target	Origin	Company	Indication
MAbs against viral antigens
3 mAb cocktail C2F5, C2G12, and C4E10	Anti-Gp41, anti-glycan structure of Gp120	Human mAb	Rockefeller University	Therapy of HIV infection Phase I/II
P2G12	Anti-glycan structure of Gp120	Human mAb	University of Surrey European Commission	Prevention of HIV infection Phase I
KD-247	Anti-V3 loop of HIV-1 Env	Humanized mAb	The Chemo-Sero-Therapeutic Research Institute	Therapy of HIV infection Phase I
F105	Anti-Gp120, CD4 binding site	Human mAb	National Institute of Allergy and Infectious Diseases (NIAID)	Therapy of HIV infection Phase I
MBL-HCV1	Anti-E2	Human mAb	MassBiologics	Prevention of liver reinfection with HCV after transplantation Phase II
MAbs against host antigens
IBALIZUMAB	Anti-CD4 receptor	Humanized mAb	TaiMed Biologics/Tanox	Therapy of HIV infection Phase I/II
PRO-140	Anti-CCR5 receptor	Humanized mAb	Progenics/PDL	Therapy of HIV infection Phase I/II
CCR5mAb004	Anti-CCR5 receptor	Human mAb	Human Genome Sciences	Therapy of HIV infection Phase I
BAVITUXIMAB	Anti-phosphatidyl serine.	Chimeric mAb	Peregrine Pharmaceuticals	Therapy of HIV/HCV co-infection Phase II	Therapy of chronic HCV infection co-administrated with ribavirin Phase II
Immunomodulatory mAbs
TREMELIMUMAB CP 675,206	Anti-CTLA-4	Humanized mAb	Pfizer	Therapy of HIV infection Phase I (study withdrawn prior to enrollment)	Therapy of advanced HCC in HCV infected patient Phase II
CT-011	Anti-PD-1	Humanized mAb	CureTech	Therapy of chronic HCV infection Phase I/II
BMS 936558 (MDX1106)	Anti-PD-1	Human mAb	Bristol-Myers Squibb/Medarex	Therapy of chronic HCV infection Phase I